Introduction. Hypertrophic cardiomyopathy (HCM), an inherited primary cardiac disorder mostly caused by defective sarcomeric proteins, serves as a model to investigate left ventricular hypertrophy (LVH). HCM manifests extreme variability in the degree and distribution of LVH, even in patients with the same causal mutation. Genes coding for renin-angiotensin-aldosterone system components have been studied as hypertrophy modifiers in HCM, with emphasis on the angiotensin (Ang) II type 1 receptor (AT 1 R). However, Ang II binding to Ang II type 2 receptors (AT 2 R) also has hypertrophy-modulating effects. Methods. We investigated the effect of the functional +1675 G/A polymorphism (rs1403543) and additional single nucleotide polymorphisms in the 3' untranslated region of the AT 2 R gene (AGTR2) on a heritable composite hypertrophy score in an HCM family cohort in which HCM founder mutations segregate. Results. We find significant association between rs1403543 and hypertrophy, with each A allele decreasing the average wall thickness by ~0.5 mm, independent of the effects of the primary HCM causal mutation, blood pressure and other hypertrophy covariates (p = 0.020).
Introduction
Hypertrophic cardiomyopathy (HCM), a primary cardiac disorder characterised by left ventricular hypertrophy (LVH), serves as a model to investigate hypertrophy development. 1 HCM is classically caused by mutations in genes encoding sarcomeric proteins, and to date more than 450 HCM causal mutations have been identified within sarcomeric genes. 2 However, the hypertrophic phenotype of HCM is extremely heterogeneous. Not only do distinct disease-causing mutations affect prognostic outcomes differently, 3 but extreme variability in the extent and distribution of hypertrophy is also observed in individuals from the same family with the same disease-causing mutation. 4, 5 This, as well as evidence from animal models, 6 suggests that the eventual hypertrophic phenotype of HCM is modified by the primary causal mutation as well as additional genetic and environmental factors.
Previous studies have identified genes encoding reninangiotensin-aldosterone system (RAAS) components as modifiers of the hypertrophic phenotype of HCM. [7] [8] [9] Many of these investigations focussed on the angiotensin (Ang) II type 1 receptor (AT 1 R) as binding of Ang II to this receptor elicits cellular hypertrophic effects, 10 and because clinical trials concluded that AT 1 R antagonists reduce LVH and other cardiac morbidities. 11, 12 However, Ang II is also capable of binding to Ang II type 2 receptors (AT 2 R), which results in anti-hypertrophic effects that counter the hypertrophic effects of AT 1 Rs. 13, 14 The AT 2 R gene (AGTR2) is located on the X-chromosome and consists of three exons and two introns, with the entire open reading frame of the gene situated in the third exon.
Studies on hypertensive populations have identified a functional +1675 G/A polymorphism (rs1403543) in AGTR2 that is significantly associated with LVH indices, but were discrepant regarding which of the alleles increased hypertrophy. [15] [16] [17] This discrepancy might be explained by the vulnerability of association studies to the effect of confounding variables that influence the eventual cardiovascular phenotype, if these are not adjusted for in statistical analyses. 18 While the effect of this +1675 G/A polymorphism on hypertrophy in patients with HCM is unknown, Deinum et al. 19 reported an association between a single nucleotide polymorphism (SNP) in the 3' untranslated region (UTR) of AGTR2, rs11091046, and left ventricular mass index (LVMI), observed only in female HCM patients. However, this study of ungenotyped cases did not account for differences in the primary HCM causal mutation, which may have had confounding effects on the association.
The present study therefore aimed to investigate the effect of the +1675 G/A polymorphism, rs11091046 and an additional SNP in the 3' UTR of AGTR2 on a heritable hypertrophy trait in a cohort of HCM families in which either of three HCM founder mutations segregate, while taking the HCM-causing mutation and additional hypertrophy covariates into consideration.
Methods

Subjects
The University of Stellenbosch Health Science Faculty's Institutional Review Board approved this study (N04/03/062), and all subjects entered into the study gave written informed consent. Genomic DNA for all genotypic analyses was extracted from the nuclei of peripheral blood leukocytes as described previously. 5, 20 During routine mutation screening of consecutively referred probands, 22 individuals carrying any of three mutations that occur as founder mutations in South Africa, i.e. R92W TNNT2 , R403W MYH7 , and A797T MYH7 , were identified. 20 Pedigree tracing was performed for these probands and a cohort of 353 genetically and clinically affected and unaffected family members were enrolled in the study. These individuals were all screened for the presence or absence of all three founder mutations.
Clinical evaluation
All participating individuals were clinically characterised by an experienced echocardiographer (MR) who was blinded to the mutation status of each subject. A total of 16 2D-echocardiographic measurements of wall thickness at the mitral valve, papillary muscle and apex levels were taken according to recommendations of the American Society of Echocardiography, 21 as described previously. 3 These measurements were used to generate a composite score of the 16 wall thickness measurements that offered the best representation of the variability in hypertrophy seen in our cohort, by means of principal component analysis.
Blood pressure (BP) measurements were taken twice in the sitting position, after 5 min of rest, and the second measurement used. Subjects were identified as hypertensive if they were on anti-hypertensive medication or if they had a systolic BP ≥ 140 mm Hg or diastolic BP ≥ 90 mm Hg. We derived resting heart rate (HR) from standard electrocardiography performed on a MAC1200ST after 5 min of rest. Medical history and additional covariates of cardiac structure (age, sex and body surface area (BSA)) were recorded for each participant.
AGTR2 genotyping
Genotypes were determined on all DNA samples for the variants listed in table 1, using ABI TaqMan Validated SNP Genotyping Assays (Applied Biosystems, Foster City CA, USA). Rs1403543 (+1675 G/A) is located in intron 1 of AGTR2, while rs5194 and rs11091046 both occur in the 3' UTR of AGTR2.
Polymerase chain reaction (PCR) amplification for each SNP was performed in 5 μl reactions in thermostable 
Statistical analyses
All statistical analyses, unless mentioned otherwise, were done in R and R packages (www.r-project.org). Validation of input files and Mendelian inheritance within families were verified with Pedstats v. 6.11 22 using X-chromosome settings, and genotyping inconsistencies were resolved by re-genotyping. Pedstats was also used to assess Hardy-Weinberg equilibrium (HWE) on unrelated individuals within the cohort. Haploview v. 4.1 23 was used to estimate minor allele frequencies, linkage disequilibrium (LD) and testing HWE, using X-chromosome settings.
Each wall thickness measurement was transformed to approximate normality using quantile normalisation 24 prior to analysis. Since not only the extent, but also the distribution of hypertrophy in HCM is highly variable, it is difficult to distinguish a single echocardiographic measure that accurately quantifies the extent of hypertrophy in all patients. Although echocardiographically derived LVM is most often used to quantify hypertrophy in HCM, it is known to be an inaccurate measure due to the variable and asymmetric nature of hypertrophy in HCM. However, a single measure that summarises the variability in the 16 quantile-normalised 2D-echocardiographic measurements most effectively is desirable also for reasons of parsimony (to protect against the inflation of type-one errors caused by doing multiple tests on the same cohort, as would happen if multiple measures of hypertrophy were analysed). Principal 25 was used to assess the (broad sense) heritability (ratio of heritable/polygenic variance component to total variance of PC1) of PC1 and LVM after adjusting for hypertrophy confounders.
As QTDT does not have the option to assess association with X-linked variants, association between the AGTR2 variants and the PC1 score was assessed with specialised mixed-effects models using per-individual random effects which are correlated according to kinship coefficients (R package kinship, function lmekin, www.r-project.org). These models include environmental and polygenic variance components. All analyses were adjusted for covariates that are known to modulate cardiac hypertrophy, namely whether the individual carries a mutation or not, the identity of the primary HCM-causing mutation (R92W TNNT2 , R403W MYH7 , or A797T MYH7 ), hypertension diagnosis, systolic BP, diastolic BP, sex, age at clinical assessment, BSA and HR (as a proxy measure for tachycardia). Such modelling results in the effect of the AGTR2 variant being estimated after the effects of the covariates have been removed from the phenotype. Atrial fibrillation, typically a late consequence of severe LVH in HCM, was present in only six of the 152 mutation carriers and was not included as a covariate in the current analysis.
We initially modelled the genotypes for females as the number of minor alleles (additive) plus a dominance term. As none of the dominance terms were significantly different from zero, we discarded them from the models. We coded the (hemizygote) men as having 0 or 1 minor alleles. We investigated an alternative coding of 0 or 2 minor alleles, but it resulted in a poorer model fit (results not shown). As we did not detect a significant interaction between sex and any of the AGTR2 variants (results not shown) on PC1, we did not analyse males and females separately. We also did not detect a significant interaction between mutation status and any of the AGTR2 variants; therefore mutation carriers did not need to be analysed separately, but could be pooled with non-carriers into a larger group for analysis.
Our models are appropriate for statistical inference (i.e. they deliver valid p-values), but provide effect estimates in terms of the change in a weighted sum of quantile-normalised hypertrophy measures, which can not be interpreted clinically. To provide effect estimates in the original units of measurement, mm, we estimated, for each variant, an approximate effect size and standard error, by modelling the mean of the 16 wall thickness measures.
Results
A total of 353 individuals belonging to seven R92W TNNT2 , three R403W MYH7 and 12 A797T MYH7 families were genotyped for AGTR2 variants. Of these, 227 individuals (including all the HCM mutation carriers) consented to clinical investigation. Descriptive statistics (median and interquartile range (first quartile and third quartile), not adjusted for any of the known hypertrophy confounders listed in the methods section), for carriers and non-carriers of each of the three HCM-causing mutations are given in table 2; descriptive statistics (mean and interquartile range) for PC1 for each genotype of the three AGTR2 SNPs are given in table 3. The allele and genotype frequencies for the complete cohort are depicted in table 4a. All genotype frequencies, in a random sample of unrelated individuals, were in agreement with HWE; the p-values and the estimated population (unrelated) minor allele frequencies are shown in table 4b. The two 3' UTR SNPs were found to be in complete LD (D' = 1.00), while incomplete LD exists between rs1403543 and rs5194 (D' = 0.67) and between rs1403543 and rs11091046 (D' = 0.65).
The first principal component, namely our composite hypertrophy score PC1, explained the majority (76%) of the variation in the 16 quantile-normalised wall thickness (table 5 ) and scores ranging from -7.9-8.3. The PC1 score (p = 0.018, H 2 = 0.38) was found to be somewhat more heritable than LVM (p = 0.028, H 2 = 0.29). We found significant evidence for association (p = 0.020) between PC1 and rs1403543 in a model adjusted for mutation carrier status, the identity of the primary HCM mutation, age, sex, systolic and diastolic blood pressure, BSA, hypertension diagnosis and HR, known hypertrophy covariates (figure 1). The corresponding estimated average reduction in wall thickness for each A allele carried, based on analysis of the mean of 16 wall thickness measures (instead of the PC1 score), is 0.48 mm (figure 1); conversely, each G allele is estimated to lead to an increase of 0.48 mm. No evidence of association was found between hypertrophy and rs11091046 (p = 0.352) or rs5194 (p = 0.307) (figure 1).
Discussion
We here report a significant association between the previously identified functional +1675 G/A polymorphism (rs1403543) and a heritable composite hypertrophy score (that takes into account extent and distribution of hypertrophy in the left ventricle) in a cohort of genotype-known HCM founder families. The A allele of this +1675 G/A polymorphism was found to significantly decrease our hypertrophy score (PC1). We estimate that, after taking the values of all the relevant confounders (mutation carrying status, sex, age and others) into account, the average wall thickness will be 0.48 mm lower for each A allele carried by an individual and, conversely, 0.48 mm greater for each G allele carried by an individual. Thus, if all other covariates were equal, one would expect a G/G homozygote's heart wall to be 0.96 mm, almost 1 mm, thicker than that of an A/A carrier. This +1675 G/A polymorphism is located at a lariat branch-point in the first intron, 29 bp before exon 2 in a region that is important for transcriptional activity. 26 Although it had been postulated that this polymorphism may affect pre-mRNA splicing, 27 a later study 28 showed that it modulates AT 2 R protein expression, rather than mRNA splicing.
In our statistical modelling, adjustments were made for hypertrophy confounders, and thus this association is independent of known hypertrophy covariates, including sex, BP, HR and the primary HCM causal mutation. However, levels of circulating angiotensin II, which, as a ligand for both AT 1 and AT 2 receptors, may also influence hypertrophy, were not available and thus not included as covariate in this study. As there is complex interplay between the multiple components of the RAAS, eventually a comprehensive analysis which focuses on the compound effect of multiple hypertrophy modifier loci within the RAAS will yield the most accurate understanding of its role in hypertrophy development.
Our results support the finding of Alfakih et al. 15 who, in hypertensive patients, reported an association between the G allele of this polymorphism and increased LVMI as determined with magnetic resonance imaging (MRI). MRI is credited with being a more precise and reproducible *Each A allele of rs1403543 significantly reduces the average wall thickness by almost 0.5 mm (p = 0.020); p-values were derived from test of modelling PC1 hypertrophy score.
measure of LVM than M-mode and 2D-echocardiography, even though echocardiography is still widely used to estimate LVM as it is more readily available as a clinical tool. 29 We circumvented this difficulty by using a composite hypertrophy score derived by principal component analysis, PC1, which best described the variability in the 16 echocardiographically determined wall thickness measurements in the present cohort. Thus we analysed a single trait that takes the extent and distribution of hypertrophy into account without resorting to a geometrically inaccurate estimate of overall hypertrophy, namely echocardiographically derived LVM. The PC1 score was, however, derived from quantilenormalised data, and the effect size following association analysis of this trait is therefore not interpretable in terms of the original cardiac measurements. Thus, we estimated the effect size from an analysis of the mean of the 16 untransformed cardiac wall thickness measurements originally used to derive PC1. The resulting effect size was modest (0.48 mm), although comparable to effect sizes reported for other RAAS candidate modifiers, 30, 31 which suggests that the eventual hypertrophic phenotype of HCM might be the cumulative result of a number of modifier genes of modest effect.
Our results and those of Alfakih et al. 15 are in contrast to those previously reported by Schmieder and colleagues 16 as well as by Herrmann et al., 17 who found an association between the +1675 A allele and an increase in echocardiographically determined LVM in males only. This finding was, however, not replicated in a larger cohort and those authors subsequently concluded that further research into the role of AGTR2 in LVH was needed. 17 Unlike Deinum and colleagues, who previously reported an association between rs11091046 in the 3' UTR of AGTR2 and LVMI in female patients with HCM, 19 we did not find any significant evidence of an association between either of the two 3' UTR SNPs and hypertrophy. One explanation for this discrepancy could be that, unlike the previous study, 19 this study adjusted all analyses for the primary HCM causal mutation and did not make use of the geometrically inaccurate echocardiographically derived LVMI. 32 Although we specifically tested the interaction between sex and the genotypes generated in this study, we also found no statistically significant interaction with either gender; consequently we did not analyse males and females separately. We did, however, include sex as a covariate in the association analysis due to the known effect of gender on hypertrophy development.
Despite a modest sample size, the use of founder HCM families in this study provided certain benefits over casecontrol designs as it offers additional quality control measures to ensure genotyping accuracy and the opportunity to circumvent the confounding effect of undetected population stratification. Furthermore, populations carrying founder mutations provide added control over the genetic variability introduced by different HCM causal mutations.
In conclusion, this study confirms the previous suggestion of association between the functional +1675 G/A SNP and cardiac hypertrophy, and is the first to report an association between this genetic variant and hypertrophy in HCM, using a novel approach to quantify the extent and degree of hypertrophy. Previously it had been suggested that the +1675 G/A polymorphism could serve as a marker for hypertensive individuals that would benefit from pharmaceutical intervention; 15 our results further suggest that +1675 G/A SNP could potentially be used in the context of a profile of markers that are indicative of an increased genetic predisposition to LVH development also in patients with HCM.
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